Savient Pharmaceuticals, Inc.
One Tower Center
14th Floor
East Brunswick,
NJ 08816
United States - Map
Phone: 732-418-9300
Fax: 732-418-0570
Website: http://www.savientpharma.com
Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. Savient Pharmaceuticals, Inc. sells its products through specialty and wholesale distributors. The company was formerly known as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in June 2003. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in East Brunswick, New Jersey. Key Statistics
| |
| Savient Pharmaceuticals, Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Low Concern), Compensation (Low Concern), Shareholder Rights (Low Concern). | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. David Y. Norton ,
60
Interim Chief Exec. Officer and Director | 4.00K | N/A | Mr. Kenneth J. Zuerblis ,
53
Chief Financial Officer, Chief Accounting Officer, Exec. VP and Treasurer | 153.00K | 0.00 | Mr. Philip K. Yachmetz J.D.,
55
Sr. VP, Gen. Counsel and Sec. | 493.00K | 0.00 | Mr. Richard P. Crowley ,
55
Exec. VP of Biopharmaceutical Operations | 368.00K | 0.00 | Dr. Kenneth M. Bahrt M.D.,
59
Chief Medical Officer and Sr. VP | 328.00K | 0.00 |
|
| | Amounts are as of Dec 30, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.60% Nasdaq 
0.10(13.05%) May 25, 4:00PM EDT|After Hours:
0.86